Literature DB >> 4307990

2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.

L M Cobb, T A Connors, L A Elson, A H Khan, B C Mitchley, W C Ross, M E Whisson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4307990     DOI： 10.1016/0006-2952(69)90267-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  19 in total

Review 1.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

2.  DNA sense-and-respond protein modules for mammalian cells.

Authors:  Shimyn Slomovic; James J Collins
Journal:  Nat Methods       Date:  2015-09-21       Impact factor: 28.547

Review 3.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 4.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

5.  Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.

Authors:  Toru Shibata; Amato J Giaccia; J Martin Brown
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

6.  Prodrugs in Cancer Chemotherapy.

Authors:  Richard J Knox; Tom A Connors
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

7.  CB 1954 revisited. II. Toxicity and antitumour activity.

Authors:  P Workman; J E Morgan; K Talbot; K A Wright; J Donaldson; P R Twentyman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  CB 1954 revisited. I. Disposition kinetics and metabolism.

Authors:  P Workman; R A White; K Talbot
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 9.  The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  R J Knox; F Friedlos; M P Boland
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

10.  Evaluating aziridinyl nitrobenzamide compounds as leishmanicidal prodrugs.

Authors:  Andrew A Voak; Karin Seifert; Nuala A Helsby; Shane R Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.